IN2014MN00023A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00023A
IN2014MN00023A IN23MUN2014A IN2014MN00023A IN 2014MN00023 A IN2014MN00023 A IN 2014MN00023A IN 23MUN2014 A IN23MUN2014 A IN 23MUN2014A IN 2014MN00023 A IN2014MN00023 A IN 2014MN00023A
Authority
IN
India
Prior art keywords
dazol
facture
manu
propan
trifluoro
Prior art date
Application number
Other languages
English (en)
Inventor
Helena Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Astrazeneca Ab
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Bayer Ip Gmbh filed Critical Astrazeneca Ab
Publication of IN2014MN00023A publication Critical patent/IN2014MN00023A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN23MUN2014 2011-06-29 2012-06-27 IN2014MN00023A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
IN2014MN00023A true IN2014MN00023A (pt) 2015-06-12

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
IN23MUN2014 IN2014MN00023A (pt) 2011-06-29 2012-06-27

Country Status (16)

Country Link
EP (1) EP2726464A1 (pt)
JP (1) JP2014527955A (pt)
KR (1) KR20140036230A (pt)
CN (1) CN103814015A (pt)
AR (1) AR086818A1 (pt)
AU (1) AU2012277514A1 (pt)
BR (1) BR112013031759A2 (pt)
CA (1) CA2839398A1 (pt)
IN (1) IN2014MN00023A (pt)
MX (1) MX2013014566A (pt)
RU (1) RU2013153466A (pt)
SG (1) SG195309A1 (pt)
TW (1) TW201305115A (pt)
UY (1) UY34170A (pt)
WO (1) WO2013001294A1 (pt)
ZA (1) ZA201309480B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
EP4253396A4 (en) * 2020-11-27 2024-09-11 Mirailab Bioscience Inc HIGHLY PURIFIED BETA-NICOTINAMIDE MONONUCLEOIDE (NMN) AND METHOD FOR ITS PRODUCTION
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
NZ605149A (en) 2010-07-21 2014-08-29 Astrazeneca Ab Inhaler
RU2013104637A (ru) 2010-07-21 2014-08-27 Астразенека Аб Ингалятор

Also Published As

Publication number Publication date
TW201305115A (zh) 2013-02-01
UY34170A (es) 2013-01-31
ZA201309480B (en) 2015-10-28
BR112013031759A2 (pt) 2016-12-13
AR086818A1 (es) 2014-01-22
MX2013014566A (es) 2014-09-25
JP2014527955A (ja) 2014-10-23
CA2839398A1 (en) 2013-01-03
WO2013001294A1 (en) 2013-01-03
CN103814015A (zh) 2014-05-21
AU2012277514A1 (en) 2014-01-09
KR20140036230A (ko) 2014-03-25
RU2013153466A (ru) 2015-08-10
EP2726464A1 (en) 2014-05-07
SG195309A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
IL248246B (en) (5r,2s)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (5r,2s)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of anti-infective drugs
PH12014502524A1 (en) Carboxylic acid compounds
MX338916B (es) Oxazepinas como moduladores del canal de iones.
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
MX336810B (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
MX2013014007A (es) [1,3] oxazinas.
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MD20120050A2 (en) New agomelatine cocrystals, process for their preparation and pharmaceutical compositions containing them
MX2014000635A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak.
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
IN2014MN00023A (pt)
IN2012DN01292A (pt)
HK1193087A1 (en) New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same vii
IL229005A (en) Pyrazolidine-3-derivatives, their process, their preparations and their use in the preparation of schizophrenia and cognitive diseases
IN2013DN02555A (pt)
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
WO2012159704A8 (en) Stable crystal modifications of dotap chloride
NZ601452A (en) Use of agomelatine in obtaining medicaments intended for the treatment of obsessive-compulsive disorder (ocd)
NZ700507A (en) Pyrimidine derivatives for the treatment of bacterial diseases
IN2014DN10683A (pt)
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
HU0900281D0 (en) Kynurenc acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use for the treatment of headache
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
EP2732822A4 (en) THERAPEUTIC AGENT AGAINST BONE BREAK, BONE GROWTH AMPLIFIER OR THERAPEUTIC OR PROPHYLACTIC AGGREGATE AGAINST BONE DISORDERS WITH CARBON DIOXIDE AS ACTIVE AGENT